Addex Therapeutics Ltd (ADXN) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone. I'd like to thank you all for attending our Q1 2025 financial results conference call. I'm here with Mikael Palinczeff, our head of Translational Finance, who will provide an update on our R&D program. I draw your attention to the press release and the financial statements issued earlier today, which are available on our website. I also draw your attention to our disclaimers. We will be making certain forward-looking statements that are based on the knowledge we have today. I will start this conference call by giving a quick overview of our recent activities and achievements before reviewing our pipeline. I will then hand over to Nisha, who will review in more detail our NGR5 megabattleset modulator program for brain injury recovery, and I'll gather the popular modulations for clinical programs for COT. I will then review our Q1 2025 financial results followed. With that, we will open the Q&A. Moving on to the highlights, we have had a great start to the year, with several significant value-creating achievements in our pipeline. We have made excellent progress in our GABA-B positive outset modulator program with our partner, Indivior, who successfully completed IND enabling studies with their selective drug candidate for substance use disorders. As a reminder, under the terms of the agreement, ADDx is eligible for payments of up to $330 million US dollars and successful achievement of pre-specified regulatory clinical and commercial market as well as tiered royalties on the level of net sales from high single digits up to low double digits. Also under the terms of the agreement, we have the right to select compounds for development in a predefined list of reserved indications. We have selected a compound to advance our own independent recovery PAM pr...